Discusses the Importance of Securing the Health of the Nation and the Security of Our Nation’s Drug Supply
Terry Novak, the Chairman & CEO of aseptic fill & finish CDMO Salubrent Pharma Services, recently appeared on The Mantell Associates Network’s podcast. The podcast shares the stories, advice and outlook of influential leaders at market-leading companies across the industry, with the goal providing exposure for the individuals and businesses currently doing great things in the Pharmaceutical & Life Science industry.
Novak spoke with Alessandro Mantell about how Salubrent is creating a new technology-focused CDMO that secures people’s health by offering flexible, state-of-the-art aseptic, fill-finish and analytical services. He also discussed how Salubrent uses the latest fill-finish technologies and a full complement of analytical development and testing services to provide clinical and commercial stage pharmaceutical and biotech companies with flexible batch production of sterile injectable products.
“Alessandro asked great questions. I thoroughly enjoyed discussing current market dynamics and what makes Salubrent’s offering so unique,” said Terry Novak, the company’s President & CEO. “I’m grateful to have had this opportunity to share what we’re doing at Salubrent with their audience.”
Listen to this episode and subscribe to the podcast on the Mantell Associates Network’s website.
ABOUT SALUBRENT PHARMA SERVICES
Salubrent Pharma Solutions is a full-service CDMO offering analytical services to clinical and commercial stage pharma and biotech companies. Founded by industry veterans with over 200 years of combined industry experience, Salubrent provides clinical and commercial stage pharma and biotech companies with the expertise needed to successfully bring their products to the clinic and eventually the market. Salubrent will soon begin construction on the first of four US-based aseptic fill-finish facilities, each located in a major biotech hub and focusing on personalized medicine and PI/II CTM batches for those companies in need of small batch production of sterile injectable products.. Analytical services will be available in 2021, with proof-of-concept commercial aseptic services launching in 2022.
Learn more at salubrent.com